Immunosuppression and skin carcinogenesis: eccrine porocarcinoma - a case report and literature review
DOI:
https://doi.org/10.51798/sijis.v7i1.1256Keywords:
Eccrine Porocarcinoma; Skin Neoplasms; Immunosuppression; Leukemia, Lymphocytic, Chronic, B-Cell; Case ReportsAbstract
The eccrine porocarcinoma (EPC) is a rare, malignant, adnexal tumor that arises either spontaneously or from a long-standing poroma and is often misdiagnosed due to the clinical and histological similarity to basal cell or squamous cell carcinoma. EPC usually affects older individuals and can manifest as nodules, plaques, or ulcerated lesions with variable morphology, earning it the title of "the great imitator." EPC has been thought to be associated with chronic immunosuppression and UV exposure. This report presents the case of CLD in a 78-year-old male with a history of chronic lymphocytic leukemia, previously treated with fludarabine-based chemotherapy. The lesion (located in the sternal notch) was excised and confirmed histologically and immunohistochemically, showing biphasic cell populations, ductal differentiation, comedonecrosis, and a high Ki-67 index. This case highlights the diagnostic complexity of EPC and its possible relationship with immunosuppressive therapy. It emphasizes the importance of dermatologic surveillance in immunocompromised patients for early identification and management of rare secondary skin malignancies.
References
Bienstman, T., Güvenç, C., & Garmyn, M. (2024). Porocarcinoma: Clinical and Histological Features, Immunohistochemistry and Outcomes: A Systematic Review. International Journal of Molecular Sciences, 25(11). https://doi.org/10.3390/ijms25115760
Cass, S. H., Tobin, J. W. D., Seo, Y. D., Gener-Ricos, G., Keung, E. Z., Burton, E. M., Davies, M. A., McQuade, J. L., Lazar, A. J., Mason, R., Millward, M., Sandhu, S., Khoo, C., Warburton, L., Guerra, V., Haydon, A., Dearden, H., Menzies, A. M., Carlino, M. S., … Ferrajoli, A. (2023). Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia. Annals of Oncology, 34(9), 796–805. https://doi.org/10.1016/j.annonc.2023.06.007
Gómez-Zubiaur, A., Medina-Montalvo, S., Vélez-Velázquez, M. D., & Polo-Rodríguez, I. (2017). Eccrine Porocarcinoma: Patient Characteristics, Clinical and Histopathologic Features, and Treatment in 7 Cases. Actas Dermo-Sifiliograficas, 108(4), e27–e32. https://doi.org/10.1016/j.ad.2016.04.024
Jarocki, C., Kozlow, J., Harms, P. W., & Schmidt, B. M. (2020). Eccrine Porocarcinoma: Avoiding Diagnostic Delay. Foot & Ankle Specialist, 13(5), 415–419. https://doi.org/10.1177/1938640020946190
Kangabam, B., & Kamei, R. (2022). Eccrine Porocarcinoma of the Chest Wall. Cureus, 14(7). https://doi.org/10.7759/cureus.26510
Le, N. S., Janik, S., Liu, D. T., Grasl, S., Faisal, M., Pammer, J., Schickinger-Fischer, B., Hamzavi, J. S., Seemann, R., & Erovic, B. M. (2020). Eccrine porocarcinoma of the head and neck: Meta-analysis of 120 cases. Head & Neck, 42(9), 2644–2659. https://doi.org/10.1002/hed.26178
Mahomed, F., Blok, J., & Grayson, W. (2008). The squamous variant of eccrine porocarcinoma: a clinicopathological study of 21 cases. Journal of Clinical Pathology, 61(3), 361–365. https://doi.org/10.1136/jcp.2007.049213
Miyamoto, K., Yanagi, T., Maeda, T., & Ujiie, H. (2022). Diagnosis and Management of Porocarcinoma. Cancers, 14(21). https://doi.org/10.3390/cancers14215232
Modi, M. B., Moshiri, A. S., Shoji, T., Mihm, M. C., Xu, X., & Elder, D. E. (2020). Occurrence of metastatic eccrine porocarcinoma in an immunosuppressed patient. Surgical and Experimental Pathology 2020 3:1, 3(1), 16-. https://doi.org/10.1186/s42047-020-00068-x
Otteni, C., Limbert, R., Dyer, J., & Miller, R. A. (n.d.). Case report : Eccrine porocarcinoma of the scalp in an immunosuppressed patient. 45–46.
Puttonen, M., Isola, J., Ylinen, O., Böhling, T., Koljonen, V., & Sihto, H. (2022). UV-induced local immunosuppression in the tumour microenvironment of eccrine porocarcinoma and poroma. Scientific Reports 2022 12:1, 12(1), 5529-. https://doi.org/10.1038/s41598-022-09490-5
Rashid, K., Ng, R., Mastan, A., Sager, D., & Hirschman, R. (2005). Accelerated growth of skin carcinoma following fludarabine therapy for chronic lymphocytic leukemia. Leukemia & Lymphoma, 46(7), 1051–1055. https://doi.org/10.1080/10428190500096989
Seo, B. F., Choi, H. J., & Jung, S. N. (2019). Eccrine porocarcinoma on the cheek. Archives of Craniofacial Surgery, 20(1), 48–50. https://doi.org/10.7181/acfs.2018.02180
Shah, M., Wald, J., & Hanke, C. W. (2023). Eruptive Squamous Cell Carcinomas Following Treatment With Fludarabine and Discussion of Treatment. Journal of Drugs in Dermatology : JDD, 22(5), 509–510. https://doi.org/10.36849/JDD.5363
Starace, M., Rapparini, L., & Cedirian, S. (2024). Skin Malignancies Due to Anti-Cancer Therapies. Cancers, 16(11). https://doi.org/10.3390/cancers16111960
Stocker, N., Alsuliman, T., Corre, E., Ricard, L., Kaoui, F., Coppo, P., Brissot, E., Dulery, R., Banet, A., Van de Wyngaert, Z., Legrand, O., Bonnin, A., Mohty, M., Malard, F., & Marjanovic, Z. (2025). Incidence and impact of other malignancies after immunochemotherapy by fludarabine, cyclophosphamide, and rituximab as frontline treatment for chronic lymphocytic leukemia: A single-center retrospective study. Clinical Hematology International, 7(1), 1–9. https://doi.org/10.46989/001c.127828
Tsiogka, A., Koumaki, D., Kyriazopoulou, M., Liopyris, K., Stratigos, A., & Gregoriou, S. (2023). Eccrine Porocarcinoma: A Review of the Literature. Diagnostics (Basel, Switzerland), 13(8). https://doi.org/10.3390/diagnostics13081431
Wallen, H., Thompson, J. A., Reilly, J. Z., Rodmyre, R. M., Cao, J., & Yee, C. (2009). Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. PloS One, 4(3). https://doi.org/10.1371/journal.pone.0004749
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Natacha Llontop Flores, Carmen Lopez Acosta, Maite Adriana Delgado Rendon, Franklin René Delgado Rendon
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
